Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$23.32

-0.25 (-1.06%)

, SCMP

Sucampo

$17.00

0.05 (0.29%)

06:49
12/26/17
12/26
06:49
12/26/17
06:49

Mallinckrodt to acquire Sucampo for $18.00 per share

Mallinckrodt (MNK) and Sucampo Pharmaceutical (SCMP) announced that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its commercial and development assets. The transaction was approved by the Boards of Directors of both companies. Sun Acquisition, a subsidiary of Mallinckrodt, will commence a cash tender offer to purchase all of the outstanding shares of Sucampo Pharmaceuticals' common stock for $18.00 per share. The total transaction value is approximately $1.2B. The acquisition is expected to be funded through borrowings under Mallinckrodt's existing revolving credit facility, a new secured term loan facility and/or cash on hand. Following the transaction, Mallinckrodt intends to utilize its significant cash generation to focus on reducing outstanding debt over time. Sucampo stockholders holding approximately 32% of the outstanding Sucampo shares have entered into a tender and support agreement for this transaction. Mallinckrodt expects accretion from the acquisition to adjusted diluted earnings per share of at least 30c in 2018 and at least double that amount in 2019, assuming a first quarter 2018 close. Guidance on the impact of the acquisition to the company's GAAP35 diluted earnings per share has not been provided due to the inherent difficulty of forecasting the timing or amount of items that would be included in calculating such impact. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and the tender of a majority of the outstanding Sucampo shares.

MNK

Mallinckrodt

$23.32

-0.25 (-1.06%)

SCMP

Sucampo

$17.00

0.05 (0.29%)

  • 27

    Feb

MNK Mallinckrodt
$23.32

-0.25 (-1.06%)

11/22/17
OPCO
11/22/17
DOWNGRADE
OPCO
Perform
Mallinckrodt downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Mallinckrodt to Perform saying he's been "flat out wrong" on the shares. The thesis of branded growth and material margin expansion has not and is unlikely to play out within the next 12-18 months, Archila tells investors in a research note. He sees "little-to-no visibility" on Acthar growth outside of management's remarks on the payer pushback/patient abandonment issues. Further, Archila is not certain whether the company can remedy the Acthar growth issue in a timely manner. He pulled his price target for Mallinckrodt shares.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/17
LEHM
12/12/17
NO CHANGE
Target $23
LEHM
Equal Weight
Mallinckrodt management keeps conviction in Acthar, says Barclays
Barclays analyst Douglas Tsao says Mallinckrodt management in meetings last week reiterated their conviction in the Acthar franchise's durability. The analyst continues to believe the franchise should prove "reasonably durable," but after Q3's miss, he does not expect a "v-shaped" recovery next year. Further, Acthar,'s pressure could worsen if additional payers implement policies that affected Q3, Tsao tells investors in a research note titled "It always comes back to Acthar." The analyst keeps an Equal Weight rating on Mallinckrodt with a $23 price target.
12/22/17
WELS
12/22/17
NO CHANGE
WELS
Market Perform
Wells says tax act net effect seems positive for Mallinckrodt non-GAAP EPS
After Mallinckrodt released a regulatory filing this morning stating the company's anticipated puts and takes related to the passage of the U.S. Tax Cut and Jobs Act, Wells Fargo analyst David Maris said he believes the net effect of the TCJA seems positive for the company's non-GAAP EPS. Maris keeps a Market Perform rating on Mallinckrodt shares.
SCMP Sucampo
$17.00

0.05 (0.29%)

11/14/17
RILY
11/14/17
INITIATION
Target $14
RILY
Buy
Sucampo initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started Sucampo Pharmaceuticals with a Buy rating and $14 price target.
12/07/17
MAXM
12/07/17
NO CHANGE
Target $23
MAXM
Buy
Sucampo shares undervalued based on fundamentals, says Maxim
Following a Bloomberg report that said Sucampo may be entertaining suitors, Maxim analyst Jason Kolbert said this would be plausible given that the company's shares are undervalued, it is generating free cash flow and has a strong pipeline. However, he has no specific knowledge to confirm the report, Kolbert adds. He has a Buy rating and $23 price target on Sucampo shares.
12/18/17
NOMU
12/18/17
INITIATION
Target $43
NOMU
Buy
Sucampo initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Sucampo with a Buy rating and $43 price target, stating that he believes its current valuation primarily reflects cash flows from its currently marketed drug, Amitiza, and neglects potentially newer pipeline products that could double revenues to $500M by 2020.
12/19/17
12/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Michael Kors (KORS) was initiated with a Buy at Needham while Tapestry (TPR) was initiated with a Hold. 2. Sherwin-Williams (SHW) initiated with a Strong Buy, named a Top Pick at Raymond James. 3. Sucampo (SCMP) initiated with a Buy at Nomura Instinet. 4. Semtech (SMTC) initiated with a Neutral at Piper Jaffray. 5. Mimecast (MIME) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SOGO

Sogou

$11.24

-0.203 (-1.77%)

13:10
01/22/18
01/22
13:10
01/22/18
13:10
Options
Call buyers sizing up Sogou and implied volatility reaches 52-week highs »

Call buyers sizing up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

SAP

SAP

$112.47

-0.73 (-0.64%)

13:02
01/22/18
01/22
13:02
01/22/18
13:02
Hot Stocks
SAP to invest over EUR2B in France over five years »

SAP CEO Bill McDermott…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VZ

Verizon

$52.81

0.895 (1.72%)

13:00
01/22/18
01/22
13:00
01/22/18
13:00
Options
Bold pre-earnings play in Verizon »

Bold pre-earnings play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

EADSY

Airbus

$28.43

0.755 (2.73%)

, BA

Boeing

$340.46

2.7261 (0.81%)

12:56
01/22/18
01/22
12:56
01/22/18
12:56
Periodicals
Air Lease CEO: Airbus planning response to new Boeing jet, Reuters says »

Airbus (EADSY) intends to…

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$340.46

2.7261 (0.81%)

AL

Air Lease

$49.02

0.31 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

  • 22

    Feb

ADP

ADP

$121.44

0.54 (0.45%)

, CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

12:55
01/22/18
01/22
12:55
01/22/18
12:55
Conference/Events
Stephens enterprise software analyst holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$121.44

0.54 (0.45%)

CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

ORCL

Oracle

$50.48

-0.1 (-0.20%)

PAYC

Paycom

$92.03

0.84 (0.92%)

PCTY

Paylocity

$49.99

0.33 (0.66%)

SAP

SAP

$112.50

-0.7 (-0.62%)

ULTI

Ultimate Software

$227.99

-0.84 (-0.37%)

WDAY

Workday

$114.11

0.83 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 13

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

HBI

Hanesbrands

$22.94

-0.26 (-1.12%)

12:50
01/22/18
01/22
12:50
01/22/18
12:50
Options
Hanesbrands puts and calls drawing interest Monday »

Hanesbrands puts and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$45.47

0.66 (1.47%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Hot Stocks
Intel found root cause for Broadwell and Haswell platform issues »

Intel's Navin Shenoy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

QD

Qudian

$12.50

0.1 (0.81%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$44.82

0.34 (0.76%)

12:44
01/22/18
01/22
12:44
01/22/18
12:44
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel says made good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

INTC

Intel

$44.82

0.34 (0.76%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel recommends stopping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

BAC

Bank of America

$31.76

0.04 (0.13%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Periodicals
Bank of America eliminates remaining free-checking eBanking accounts, WSJ says »

Bank of America has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MS

Morgan Stanley

$57.02

-0.44 (-0.77%)

12:38
01/22/18
01/22
12:38
01/22/18
12:38
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$45.78

2.43 (5.61%)

12:35
01/22/18
01/22
12:35
01/22/18
12:35
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

12:30
01/22/18
01/22
12:30
01/22/18
12:30
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

12:25
01/22/18
01/22
12:25
01/22/18
12:25
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

OMER

Omeros

$16.70

-0.02 (-0.12%)

12:24
01/22/18
01/22
12:24
01/22/18
12:24
Hot Stocks
Omeros off highs following cautious Twitter mention »

Shares of Omeros are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

, SPX

S&P 500

12:21
01/22/18
01/22
12:21
01/22/18
12:21
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Schumer says deal reached…

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$12.59

0.12 (0.96%)

12:20
01/22/18
01/22
12:20
01/22/18
12:20
Options
AMD attracts a bullish three-way spread before shares tick higher »

AMD attracts a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BG

Bunge

$80.40

2.84 (3.66%)

, ADM

Archer Daniels

$42.21

1.2505 (3.05%)

12:19
01/22/18
01/22
12:19
01/22/18
12:19
Recommendations
Bunge, Archer Daniels, Glencore analyst commentary  »

Credit Suisse says Archer…

BG

Bunge

$80.40

2.84 (3.66%)

ADM

Archer Daniels

$42.21

1.2505 (3.05%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

$NSD

NASDAQ Market Internals

12:17
01/22/18
01/22
12:17
01/22/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/22/18
01/22
12:16
01/22/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.78

0.16 (0.24%)

12:15
01/22/18
01/22
12:15
01/22/18
12:15
Options
Kellogg put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

12:10
01/22/18
01/22
12:10
01/22/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

12:08
01/22/18
01/22
12:08
01/22/18
12:08
General news
On The Fly: Top stock stories at midday »

Stocks opened mixed, with…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

VR

Validus

$67.50

20.775 (44.47%)

SNY

Sanofi

$43.23

-1.37 (-3.07%)

CELG

Celgene

$102.65

0.93 (0.91%)

AIG

AIG

$61.03

-0.525 (-0.85%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

SANM

Sanmina

$35.45

0.5 (1.43%)

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

FE

FirstEnergy

$33.23

3.83 (13.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 02

    Feb

  • 09

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

  • 30

    Jun

  • 30

    Jun

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Periodicals
Senators have enough votes to end government shutdown, NBC reports 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.